CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
If you want minimal turnover, this guide highlights index funds with the least turnover and how to assess them for your portfolio.
27,312 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
A retiree paid off her mortgage with a lump-sum 401(k) withdrawal, only to see Medicare IRMAA add $487 to her monthly...
As Wiley (WLY) gears up for its 2026 earnings, investors should focus on segment growth, margin trajectory, and the c...
For the first time, the majority of two-parent households with children work full-time. New Census data analyzed by P...
From a 15-year-old intern to NBC’s Nightly News anchor, this profile examines the financial lessons behind a high-pro...
Rivian has made bold moves in a high-stakes market. With shares drifting down this year, this guide weighs the case f...
delek holdings rallied today captured market attention as a mid-cap refiner with jet-fuel exposure and a strategic st...
VanEck's GENZ pivots from casino-heavy holdings to growth stocks like Uber and NetEase, reshaping its dividend story ...
Three legendary investors are loading up on a single AI stock that's trading at a discount to its long‑term value. Th...
Intel shares retreat after a rally fueled by Lip-Bu Tan’s turnaround plan, as investors await Q2 results and the AI d...
Private AI leaders OpenAI and Anthropic see valuations near $1 trillion as investors chase growth. A cooling IPO wind...
Qualcomm unveils a bold AI-backed diversification plan led by CIO Attila Tinic, targeting data centers, automotive an...